Clinical Trials Logo

PTEN Loss clinical trials

View clinical trials related to PTEN Loss.

Filter by:
  • None
  • Page 1

NCT ID: NCT03971318 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL

Start date: May 5, 2017
Phase:
Study type: Observational [Patient Registry]

With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Recent clinical studies of COG in the United States and LMB in France have confirmed that molecular biological markers such as Notch1, PTEN and LOH6q are significantly associated with the prognosis of T-lymphoblastic lymphoma (T-LBL). These molecular biological markers should be included in the new risk stratification system. High-intensity treatment of high-risk patients will improve survival. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. SCCCG-LBL-2017 was formulated by South China Children's Cancer Group of Non-Hodgkin lymphoma, which mainly updated in clinical staging, efficacy evaluation, risk stratification, treatment,etc..